HER2 gene status in primary breast cancers and matched distant metastases

Breast Cancer Research

Volumn 9, Issue 3, 2007, Pages

  Tapia, Coya ^a   Savic, Spasenija ^a   Wagner, Urs ^b   Schönegg, René ^c   Novotny, Hedvika ^a   Grilli, Bruno ^a   Herzog, Michelle ^a   Barascud, Audrey DeVito ^a   Zlobec, Inti ^a   Cathomas, Gieri ^a   Terracciano, Luigi ^a   Feichter, Georg ^a   Bubendorf, Lukas ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Institut Dr Viollier   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CELL HETEROGENEITY; CHROMOSOME 17; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; TUMOR VOLUME; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENETICS; METASTASIS; PATHOLOGY; PROTO ONCOGENE;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2;

EID: 34548554590     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1676     Document Type: Article

References (44)

1. Di Fiore PP Pierce JH Kraus MH Segatto O King CR Aaronson SA erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells Science 1987, 237:178-182 10.1126/science.2885917 2885917
2. Kauraniemi P Kallioniemi A Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer Endocr Relat Cancer 2006, 13:39-49 10.1677/erc.1.01147 16601278
3. Rajkumar T Gullick WJ The type I growth factor receptors in human breast cancer Breast Cancer Res Treat 1994, 29:3-9 10.1007/BF00666177 7912566
4. Hanna W Kahn HJ Trudeau M Evaluation of HER-2/neu (erbB-2) status in breast cancer: From bench to bedside Mod Pathol 1999, 12:827-834 10463486
5. Zhang D Salto-Tellez M Do E Putti TC Koay ES Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays Hum Pathol 2003, 34:362-368 10.1053/hupa.2003.60 12733117
6. De Potter CR Schelfhout AM The neu-protein and breast cancer Virchows Arch 1995, 426:107-115 10.1007/BF00192631 7757280
7. Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235:177-182 10.1126/science.3798106 3798106
8. Plosker GL Keam SJ Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer Drugs 2006, 66:449-475 10.2165/00003495-200666040-00005 16597163
9. Baselga J Tripathy D Mendelsohn J Baughman S Benz CC Dantis L Sklarin NT Seidman AD Hudis CA Moore J Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer Semin Oncol 1999, 26:78-83 10482197
10. Leyland-Jones B Trastuzumab: Hopes and realities Lancet Oncol 2002, 3:137-144 10.1016/S1470-2045(02)00676-9 11902499
11. Tripathy D Slamon DJ Cobleigh M Arnold A Saleh M Mortimer JE Murphy M Stewart SJ Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 2004, 22:1063-1070 10.1200/JCO.2004.06.557 15020607
12. Tuma RS Trastuzumab trials steal show at ASCO meeting J Natl Cancer Inst 2005, 97:870-871 15956644
13. Press MF Hung G Godolphin W Slamon DJ Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression Cancer Res 1994, 54:2771-2777 7909495
14. Pauletti G Dandekar S Rong H Ramos L Peng H Seshadri R Slamon DJ Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry J Clin Oncol 2000, 18:3651-3664 11054438
15. Tapia C Schraml P Simon R Al-Kuraya KS Maurer R Mirlacher M Novotny H Spichtin H Mihatsch MJ Sauter G HER2 analysis in breast cancer: Reduced immunoreactivity in FISH non-informative cancer biopsies Int J Oncol 2004, 25:1551-1557 15547690
16. Mass RD Press MF Anderson S Cobleigh MA Vogel CL Dybdal N Leiberman G Slamon DJ Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 2005, 6:240-246 16137435
17. Press MF Sauter G Bernstein L Villalobos IE Mirlacher M Zhou JY Wardeh R Li YT Guzman R Ma Y Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials Clin Cancer Res 2005, 11:6598-6607 10.1158/1078-0432.CCR-05-0636 16166438
18. Gokhale S Gatalica Z Mohammad A Rampy AI Velagaleti Gopalrao VN FISH for HER-2/neu in breast cancer: Standardization makes the difference! Indian J Cancer 2004, 41:152-158 15659867
19. Gong Y Booser DJ Sneige N Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma Cancer 2005, 103:1763-1769 10.1002/cncr.20987 15786420
20. Gancberg D Di Leo A Cardoso F Rouas G Pedrocchi M Paesmans M Verhest A Bernard-Marty C Piccart MJ Larsimont D Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 2002, 13:1036-1043 10.1093/annonc/mdf252 12176781
21. Regitnig P Schippinger W Lindbauer M Samonigg H Lax SF Change of HER-2/ neu status in a subset of distant metastases from breast carcinomas J Pathol 2004, 203:918-926 10.1002/path.1592 15258994
22. Bozzetti C Personeni N Nizzoli R Guazzi A Flora M Bassano C Negri F Martella E Naldi N Franciosi V HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma Cancer 2003, 99:310-315 10.1002/cncr.11731 14579298
23. Tanner M Jarvinen P Isola J Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer Cancer Res 2001, 61:5345-5348 11454672
24. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up Histopathology 1991, 19:403-410 10.1111/j.1365-2559.1991.tb00229.x 1757079
25. Kononen J Bubendorf L Kallioniemi A Barlund M Schraml P Leighton S Torhorst J Mihatsch MJ Sauter G Kallioniemi OP Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 1998, 4:844-847 10.1038/nm0798-844 9662379
26. Goldhirsch A Glick JH Gelber RD Coates AS Thurlimann B Senn HJ Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 2005, 16:1569-1583 10.1093/annonc/ mdi326 16148022
27. Ross JS Fletcher JA Bloom KJ Linette GP Stec J Symmans WF Pusztai L Hortobagyi GN Targeted therapy in breast cancer: The HER-2/neu gene and protein Mol Cell Proteomics 2004, 3:379-398 10.1074/mcp.R400001-MCP200 14762215
28. Di Leo A Dowsett M Horten B Penault-Llorca F Current status of HER2 testing Oncology 2002, 63:25-32 10.1159/000066204 12422052
29. Cobleigh MA Vogel CL Tripathy D Robert NJ Scholl S Fehrenbacher L Wolter JM Paton V Shak S Lieberman G Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 1999, 17:2639-2648 10561337
30. Simon R Nocito A Hubscher T Bucher C Torhorst J Schraml P Bubendorf L Mihatsch MM Moch H Wilber K Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 2001, 93:1141-1146 10.1093/jnci/93.15.1141 11481385
31. Bilous M Dowsett M Hanna W Isola J Lebeau A Moreno A Penault-Llorca F Ruschoff J Tomasic G van de Vijver M Current perspectives on HER2 testing: A review of national testing guidelines Mod Pathol 2003, 16:173-182 10.1097/01.MP.0000052102.90815.82 12591971
32. Elkin EB Weinstein MC Winer EP Kuntz KM Schnitt SJ Weeks JC HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis J Clin Oncol 2004, 22:854-863 10.1200/ JCO.2004.04.158 14990641
33. Gong Y Gilcrease M Sneige N Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility Mod Pathol 2005, 18:1015-1021 10.1038/ modpathol.3800432 15861212
34. Persons DL Tubbs RR Cooley LD Dewald GW Dowling PK Du E Mascarello JT Rao KW Wilson KS Wolff DJ HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists Arch Pathol Lab Med 2006, 130:325-331 16519559
35. Kunitomo K Inoue S Ichihara F Kono K Fujii H Matsumoto Y Ooi A A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel Hum Pathol 2004, 35:379-381 10.1016/j.humpath.2003.05.003 15017597
36. Sekido Y Umemura S Takekoshi S Suzuki Y Tokuda Y Tajima T Osamura RY Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation Int J Oncol 2003, 22:1225-1232 12738987
37. Shin SJ Hyjek E Early E Knowles DM Intratumoral heterogeneity of her-2/ neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray Int J Surg Pathol 2006, 14:279-284 10.1177/1066896906293055 17041191
38. Moriki T Takahashi T Ueta S Mitani M Ichien M Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: Correlation with histologic sections determinations and diagnostic pitfalls Diagn Cytopathol 2004, 30:251-256 10.1002/dc.20007 15048960
39. Sauter G Feichter G Torhorst J Moch H Novotna H Wagner U Durmuller U Waldman FM Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies Acta Cytol 1996, 40:164-173 8629392
40. Nizzoli R Guazzi A Naldi N Fraciosi V Bozzetti C HER-2/neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer Acta Cytol 2005, 49:27-30 15717751
41. Bozzetti C Nizzoli R Guazzi A Flora M Bassano C Crafa P Naldi N Cascinu S HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer Ann Oncol 2002, 13:1398-1403 10.1093/annonc/mdf217 12196365
42. Gu M Ghafari S Zhao M Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens Acta Cytol 2005, 49:471-476 16334021
43. Fitzgibbons PL Page DL Weaver D Thor AD Allred DC Clark GM Ruby SG O'Malley F Simpson JF Connolly JL Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 2000, 124:966-978 10888772
44. Ross JS Fletcher JA Linette GP Stec J Clark E Ayers M Symmans WF Pusztai L Bloom KJ The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 2003, 8:307-325 10.1634/ theoncologist.8-4-307 12897328